A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| GSK2982772 | GSK2982772 is a potent and selective receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate for the Treatment of Inflammatory Diseases. GSK2982772 is, currently in phase 2a clinical studies for psoriasis, rheumatoid arthritis, and ulcerative colitis. GSK2982772 potently binds to RIP1 with exquisite kinase specificity and has excellent activity in blocking many TNF-dependent cellular responses. RIP1 has emerged as an important upstream kinase that has been shown to regulate inflammation through both scaffolding and kinase specific functions. Uses: Designed for use in research and industrial production. Additional or Alternative Names: GSK2982772; GSK-2982772; GSK 2982772. Product Category: Inhibitors. Appearance: Solid powder. CAS No. 1622848-92-3. Molecular formula: C20H19N5O3. Mole weight: 377.4. Purity: >98%. IUPACName: (S)-5-Benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b]-[1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide. Canonical SMILES: O=C(C1=NN=C(CC2=CC=CC=C2)N1)N[C@@H]3C(N(C)C4=CC=CC=C4OC3)=O. Product ID: ACM1622848923. Alfa Chemistry ISO 9001:2015 Certified. |  |
| GSK2982772 | GSK2982772 is a potent, orally active and ATP competitive RIP1 kinase inhibitor with IC50 values of 16 nM and 20 nM for human and monkey RIP1, respectively[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1622848-92-3. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-101760. |  |
| GSK2983559 | GSK2983559 is an orally active and potent receptor interacting protein 2 (RIP2) kinase inhibitor. GSK2983559 blocks many proinflammatory cytokine responses in vivo and in human inflammatory bowel disease explant samples[1]. Uses: Scientific research. Group: Signaling pathways. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-112038A. | |
| GSK2983559 | GSK2983559 is a potent, selective and oral active inhibitor of receptor interacting protein 2 (RIP2) kinase. GSK2983559 exhibits activity in blocking many proinflammatory cytokine responses in vivo and in human inflammatory bowel disease explant samples. Synonyms: RIP2 kinase inhibitor 1; RIPK2-IN-1; GSK-2983559; GSK 2983559. CAS No. 1579965-12-0. Molecular formula: C21H23N4O7PS2. Mole weight: 538.53. |  |
| GSK2983559 active metabolite | GSK2983559 active metabolite is an active metabolite of GSK2983559. GSK2983559 active metabolite is a receptor interacting protein-2 (RIP2) kinase inhibitor extracted from patent WO/2014043446 A1, compound example 1. Uses: Scientific research. Group: Signaling pathways. CAS No. 1423186-80-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19764. | |
| GSK299115A | GSK299115A is a G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor. Synonyms: GSK299115A; GSK 299115A; GSK-299115A. 4-(3,4-dichlorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-3,4-dihydro-1H-pyridine-5-carboxamide. Grade: 98%. CAS No. 864082-35-9. Molecular formula: C20H16Cl2N4O2. Mole weight: 415.27. | |
| GSK299423 | GSK299423 is an antibiotic agent and it seems potentially effective in treating patients infected with bacteria expressing the New Delhi metallo-beta-lactamase. GSK299423 is a Type II bacterial DNA topoisomerase inhibitor under the development of GlaxoSmithKline. Early research for the treatment of Gram-negative infections and Nosocomial infections was on-going in USA. Uses: Gram-negative infections; nosocomial infections. Synonyms: GSK299423; GSK 299423; GSK-299423; 4-(2-(4-(([1,3]oxathiolo[5,4-c]pyridin-6-ylmethyl)amino)piperidin-1-yl)ethyl)-6-methoxyquinoline-3-carbonitrile. Grade: 98%. CAS No. 1352149-24-6. Molecular formula: C25H27N5O2S. Mole weight: 461.58. | |
| GSK3004774 | GSK3004774 is a potent, nonabsorbable, gastrointestinally-restricted CaSR agonist, with an EC50 of 50 nM for human and pEC50s of 7.3, 6.6 and 6.5 for human, mouse and rat, respectively. Synonyms: 1-[3-({4-[(3R)-3-{[(1S)-1-(1-Naphthyl)ethyl]amino}-1-pyrrolidinyl]benzoyl}amino)propyl]-4-piperidinecarboxylic acid; 4-Piperidinecarboxylic acid, 1-[3-[[4-[(3R)-3-[[(1S)-1-(1-naphthalenyl)ethyl]amino]-1-pyrrolidinyl]benzoyl]amino]propyl]-. Grade: ≥97%. CAS No. 2138814-32-9. Molecular formula: C32H40N4O3. Mole weight: 528.69. | |
| GSK3004774 | GSK3004774 is a potent, nonabsorbable agonist of CaSR , with an pEC 50 of 7.3, 6.6 and 6.5 for human, mouse and rat CaSR, respectively. GSK3004774 shows an EC 50 of 50 nM for human CaSR [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2138814-32-9. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-107773. | |
| GSK 3008348 | GSK 3008348 is a small molecule integrin αvβ6 antagonist, extracted from patent WO/2014154725A1, example 1. The affinity (pIC50) for the human - a 6 protein in the Fluorescence Polarisation Assay for Integrin Antagonist 1 was 8.1, whereas its affinity in the cell Adhesion Assays was for: ανβ6 (pIC50 = 8.4); ανβ3 (pIC50 = 6); ανβ5 (pIC50 = 6.9); ανβ8 (pIC50 = 7.7). Uses: Scientific research. Group: Signaling pathways. CAS No. 1629249-33-7. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19767. | |
| GSK-3008348 | GSK-3008348 is an integrin αvβ6 antagonist developed for the treatment of idiopathic pulmonary fibrosis (IPF). Synonyms: GSK 3008348; GSK3008348. Grade: 98% by HPLC. CAS No. 1629249-33-7. Molecular formula: C29H38ClN5O2. Mole weight: 524.1. | |
| GSK 3008348 hydrochloride | GSK 3008348 hydrochloride is a small molecule integrin αvβ6 antagonist, extracted from patent WO/2014154725A1, example 1. The affinity (pIC50) for the human - a 6 protein in the Fluorescence Polarisation Assay for GSK 3008348 (hydrochloride) is 8.1, whereas its affinity in the cell Adhesion Assays was for: ανβ6 (pIC50 = 8.4); ανβ3 (pIC50 = 6); ανβ5 (pIC50 = 6.9); ανβ8 (pIC50 = 7.7). Uses: Scientific research. Group: Signaling pathways. CAS No. 1629249-40-6. Pack Sizes: 1 mg; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-19767A. | |
| GSK3117391 | GSK3117391 (ESM-HDAC391) is a histone deacetylase (HDAC) inhibitor, extracted from patent WO/2008040934 A1. Uses: Scientific research. Group: Signaling pathways. Alternative Names: ESM-HDAC391; CHR-5154; HDAC-IN-3. CAS No. 1018673-42-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19772. | |
| GSK3117391 | GSK3117391, a HDAC inhibitor, was developed by GSK considering its potential effect in the treatment of arthritis and rheumatoid. It was already being terminated the phase 1 trial. Uses: Gsk3117391, a hdac inhibitor, was developed by gsk considering its potential effect in the treatment of arthritis and rheumatoid. Synonyms: GSK3117391; GSK-3117391; GSK 3117391; GSK3117391A; GSK-3117391A; GSK 3117391A; HDAC-IN-3; SCHEMBL15144242; AFDPFLDWOXXHQM-NRFANRHFSA-N; CS-5448; HY-19772; 121555-EP2295410A1. Grade: 95%. CAS No. 1018673-42-1. Molecular formula: C22H33N3O4. Mole weight: 403.52. | |
| GSK3145095 | GSK3145095 is a RIP1 kinase inhibitor with an IC 50 of 6.3 nM [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1622849-43-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-111946. | |
| GSK3145095 | GSK3145095 is an orally active RIP1 kinase inhibitor with IC50 of 6.3 nM. It potently binds to RIP1 with exquisite kinase specificity and has excellent activity in blocking RIP1 kinase-dependent cellular responses. Synonyms: GSK 3145095; GSK-3145095. CAS No. 1622849-43-7. Molecular formula: C20H17F2N5O2. Mole weight: 397.38. | |
| GSK317354A | GSK317354A is a G-Protein-Coupled Receptor Kinase 2 (GRK2) inhibitor,but no detailed information has been published yet. Synonyms: GSK317354A; GSK-317354A; GSK 317354A. 4-(4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-(6-(trifluoromethyl)pyridin-3-yl)-1,4-dihydropyrimidine-5-carboxamide. Grade: 98%. CAS No. 874119-13-8. Molecular formula: C25H18F4N6O. Mole weight: 494.45. | |
| GSK3179106 | GSK3179106 is an orally active and selective RET kinase inhibitor with IC50s of 0.4 nM, 0.2 nM for human RET and rat RET, respectively. GSK3179106 has the potential for irritable bowel syndrome (IBS) through the attenuation of post-inflammatory and stress-induced visceral hypersensitivity[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1627856-64-7. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-100459. | |
| GSK321 | GSK321 is a highly potent, selective inhibitor of mutant IDH1 enzymes, with IC50=4.6 nM against R132H, 3.8 nM against R132C and 2.9 nM against R132G. GSK321 stably decreased 2-hydroxyglutarate (2-HG) production in several different IDH1 mutant AML cells within a 2-3 week time frame ex vivo. Because of the allosteric nature of the interaction, GSK321 is able to inhibit multiple mutant forms of IDH1, which is consistent with our cell biological observations. Furthermore, GSK321 retains excellent potency in cells, since it does not compete with the tightly bound cofactor. Synonyms: (7R)-1-[(4-fluorophenyl)methyl]-N-[3-[(1S)-1-hydroxyethyl]phenyl]-7-methyl-5-(1H-pyrrole-2-carbonyl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-3-carboxamide; (7R)-1-[(4-fluorophenyl)methyl]-N-[3-[(1S)-1-hydroxyethyl]phenyl]-7-methyl-5-(1H-pyrrole-2-carbonyl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-3-carboxamide; GSK321; GSK 321; GSK-321; BDBM195601. Grade: >98%. CAS No. 1816331-63-1. Molecular formula: C28H28FN5O3. Mole weight: 501.56. | |
| GSK329 | GSK329 is a potent and selective inhibitor of cardiac-specific kinase TNNI3K (TNNI3 interacting kinase) with IC50 of 10 nM. Synonyms: GSK-329; GSK 329; N-(3,5-dichloro-4-{[6-(methylamino)pyrimidin-4-yl]oxy}phenyl)-N'-[3-(trifluoromethyl)phenyl]urea; N-[3,5-Dichloro-4-[[6-(methylamino)-4-pyrimidinyl]oxy]phenyl]-N-[3-(trifluoromethyl)phenyl]-urea. Grade: 98% by HPLC. CAS No. 1268490-12-5. Molecular formula: C19H14Cl2F3N5O2. Mole weight: 472.2. | |
| GSK329 | GSK329 is a highly potent and moderately selective TNNI3K inhibitor. Uses: Designed for use in research and industrial production. Additional or Alternative Names: GSK329; GSK-329; GSK 329. Product Category: Inhibitors. Appearance: Solid powder. CAS No. 1268490-12-5. Molecular formula: C19H14Cl2F3N5O2. Mole weight: 472.24. Purity: >98%. IUPACName: N-[3,5-Dichloro-4-[[6-(methylamino)-4-pyrimidinyl]oxy]phenyl]-N-[3-(trifluoromethyl)phenyl]-urea. Canonical SMILES: O=C(N)N(C1=CC(Cl)=C(OC2=NC=NC(NC)=C2)C(Cl)=C1)C3=CC=CC(C(F)(F)F)=C3. Product ID: ACM1268490125. Alfa Chemistry ISO 9001:2015 Certified. Categories: GSK 299423. | |
| GSK3326595 | GSK3326595, also called as EPZ015938, is an orally available and specific inhibitor of protein arginine methyltransferase 5 (PRMT5) that potently inhibits tumor growth in vitro and in vivo in animal models and has entered clinical trials for the treatment of solid tumors and non-Hodgkin's lymphoma. Synonyms: GSK-3326595; GSK 3326595; GSK3326595; EPZ015938; EPZ 015938; EPZ-015938; 6-[(1-acetylpiperidin-4-yl)amino]-N-[(2S)-3-(3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxypropyl]pyrimidine-4-carboxamide. CAS No. 1616392-22-3. Molecular formula: C24H32N6O3. Mole weight: 452.55. | |
| GSK3326595 | GSK3326595 is a protein arginine methyltransferase 5 ( PRMT5 ) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma [1] [2] [3] [4] [5]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: EPZ015938. CAS No. 1616392-22-3. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg. Product ID: HY-101563. | |
| GSK334429 hydrochloride | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. |  |
| GSK3368715 3HCl | GSK3368715 is a potent reversible inhibitor of type I protein arginine methyltransferases (PRMT) with antitumor activity. Synonyms: EPZ019997 3HCl. CAS No. 2227587-26-8. Molecular formula: C20H41Cl3N4O2. Mole weight: 475.92. | |
| GSK3368715 dihydrochloride | GSK3368715 dihydrochloride is a reversible, orally active and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor with IC50s of 3.1, 48, 1148, 5.7 and 1.7 nM for PRMT1, PRMT3, PRMT4, PRMT6 and PRMT8, respectively. It can change the methylation states of arginine, alter the use of exons, and has strong anticancer activity. Synonyms: EPZ019997 dihydrochloride; N-({3-[4,4-Bis(ethoxymethyl)cyclohexyl]-1H-pyrazol-4-yl}methyl)-N,N'-dimethyl-1,2-ethanediamine dihydrochloride; 1,2-Ethanediamine, N1-[[3-[4,4-bis(ethoxymethyl)cyclohexyl]-1H-pyrazol-4-yl]methyl]-N1,N2-dimethyl-, hydrochloride (1:2). Grade: ≥95%. CAS No. 1628925-77-8. Molecular formula: C20H40Cl2N4O2. Mole weight: 439.46. | |
| GSK3368715 dihydrochloride | GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC50=3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8)). GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) produces a shift in arginine methylation states, alters exon usage, and has strong anti-cancer activity[1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: EPZ019997 dihydrochloride. CAS No. 1628925-77-8. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-128717A. | |
| GSK343 | GSK343 is a potent, selective inhibitor of EZH2 with cellular activity. GSK343 inhibits EZH2 with an IC50 of 4nM and is over 1000-fold selective for other HMTs except EZH1 (60-fold selectivity). GSK343 inhibits H3K27 methylation in HCC1806 cells with an IC50 of <200nM as measured by immunofluorescence. GSK343 exhibited limited effects on the growth of EOC cells in conventional two-dimensional (2D) culture. In contrast, GSK343 significantly suppressed the growth of EOC cells cultured in 3D matrigel extracellular matrix (ECM), which more closely mimics the tumor microenvironment in vivo. Notably, GSK343 induces apoptosis of EOC cells in 3D but not 2D culture. In addition, GSK343 significantly inhibited the invasion of EOC cells. Synonyms: GSK343; GSK-343; GSK 343. CAS No. 1346704-33-3. Molecular formula: C31H39N7O2. Mole weight: 541.7. | |
| GSK343 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK343 | GSK343 is a highly potent and selective EZH2 inhibitor with an IC50 of 4 nM. Uses: Scientific research. Group: Signaling pathways. CAS No. 1346704-33-3. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-13500. | |
| GSK-345931A | GSK-345931A is an EP(1) receptor antagonist. It is efficient in preclinical models of inflammatory pain. Uses: Inflammatory pain. Synonyms: 869499-38-7(sodium); 6-(5'-chloro-2'-(2-methylpropoxy)(1,1'-biphenyl)-2-yl)- 2-Pyridinecarboxylic acid. Grade: 98%. CAS No. 869534-13-4. Molecular formula: C22H20ClNO3. Mole weight: 381.86. | |
| GSK-345931A sodium | GSK-345931A is an EP(1) receptor antagonist. It is efficient in preclinical models of inflammatory pain. Uses: Inflammatory pain. Synonyms: GSK-345931A sodium; GSK 345931A sodium; GSK345931A sodium; 869534-13-4(Free); 6-(5'-chloro-2'-(2-methylpropoxy)(1,1'-biphenyl)-2-yl)- 2-Pyridinecarboxylic acid sodium salt. Grade: 98%. CAS No. 869499-38-7. Molecular formula: C22H19ClNNaO3. Mole weight: 403.83. | |
| GSK-3484862 | GSK-3484862 is a non-covalent inhibitor for DNA methyltransferase (Dnmt1). GSK-3484862 induces DNA hypomethylation to against cancer. GSK-3484862 mediates dramatic demethylation in murine embryonic stem cells with minimal non-specific toxicity[1][2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2170136-65-7. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 50 mg. Product ID: HY-135146. | |
| GSK3532795 | GSK3532795 (BMS-955176) is a potent, orally active, second-generation HIV-1 maturation inhibitor, with EC 50 s of 1.9, 10.2, 2.7 and 13 nM for HIV-1 WT, HIV-1 WT(human serum), HIV-1 V370A, and HIV-1 ΔV370, respectively [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: BMS-955176. CAS No. 1392312-45-6. Pack Sizes: 1 mg. Product ID: HY-112714. | |
| GSK-356278 | GSK-356278 is a selective Type 4 cyclic nucleotide phosphodiesterase inhibitor. It shows anxiolytic and cognition-enhancing effects and it has the ability to elevate cAMP in various cell types of the central nervous system. No development was reported for phase-I development in Major depressive disorder and Huntington's-disease. Uses: Huntington's disease; major depressive disorder. Synonyms: GSK-356278; GSK356278; GSK 356278; 5-(5-((2,4-dimethyl-5-thiazolyl)methyl)-1,3,4-oxadiazol-2-yl)-1-ethyl-n-(tetrahydro-2H-pyran-4-yl)-1H-Pyrazolo(3,4-b)pyridin-4-amine. Grade: 98%. CAS No. 720704-34-7. Molecular formula: C21H25N7O2S. Mole weight: 439.54. | |
| GSK360A | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopyenzyme activators, inhibitors & substrates. | |
| GSK360A | GSK360A orally active HIF-PHD inhibitor. GSK360A exerts systemic and local effects by stabilizing HIF-1α signaling and improves long-term ventricular function, remodeling, and vascularity in a model of established ventricular dysfunction. These findings suggest that GSK360A may be suitable for the treatment of post-MI remodeling and heart failure. Group: Biochemicals. Alternative Names: N- [ [1- (2-Cyclopropylethyl) -6-fluoro-1, 2-dihydro-4-hydroxy-2-oxo-3-quinolinyl] carbonyl] glycine; N- [ [1- (2-Cyclopropylethyl) -6-fluoro-4-hydroxy-2-oxo-1, 2-dihydro-3-quinolinyl] carbonyl] glycine. Grades: Highly Purified. CAS No. 931399-19-8. Pack Sizes: 5mg. US Biological Life Sciences. |  Worldwide |
| GSK3685032 | GSK3685032 is a non-time-dependent, non-covalent, first-in-class reversible and selective inhibitor of DNMT1, with IC50 of 0.036 μM. GSK3685032 induces robust loss of DNA methylation, transcriptional activation, and cancer cell growth inhibition. Synonyms: GSK-3685032; GSK 3685032. CAS No. 2170137-61-6. Molecular formula: C22H24N6OS. Mole weight: 420.53. | |
| GSK-3685032 | GSK-3685032 is a non-time-dependent, noncovalently, first-in-class reversible DNMT1-selective inhibitor, with an IC50 of 0.036 ?M. GSK-3685032 induces robust loss of DNA methylation, transcriptional activation, and cancer cell growth inhibition[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2170137-61-6. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-139664. | |
| GSK369796 Dihydrochloride | SK369796, also known as N-tert-butylisoquine, shows antimalerial activity with IC50 values of 11.2 nM for 3D7 strain, 12.6 nM for HB3 strain, 17.6 nM for K1 strain. GSK369796 was rationally designed based on chemical, toxicological, pharmacokinetic, and pharmacodynamic considerations and was selected based on excellent activity against Plasmodium falciparum in vitro and rodent malaria parasites in vivo. Synonyms: 2-[(tert-Butylamino)methyl]-5-[(7-chloroquinolin-4-yl)amino]phenol Dihydrochloride; GSK369796 Dihydrochloride; GSK 369796; GSK-369796; GSK369796; N-tert-Butyl isoquine. CAS No. 1010411-21-8. Molecular formula: C20H24Cl3N3O. Mole weight: 428.78. | |
| GSK376501A | GSK376501A is a bio-active chemical compound used for the treatment of type 2 diabetes and hypercholesterolemia. It was developed by GlaxoSmithKline and was once in clinic phase 1, but now it has been terminated. Uses: Gsk376501a is used for the treatment of type 2 diabetes and hypercholesterolemia. Synonyms: GSK-376501A; GSK376501; GSK-376501; 1-[[3,5-bis(2-methoxyethoxy)phenyl]methyl]-3-(4-tert-butylphenyl)indole-2-carboxylic acid; 1H-Indole-2-carboxylic acid, 1-((3,5-bis(2-methoxyethoxy)phenyl)methyl)-3-(4-(1,1-dimethylethyl)phenyl)-. Grade: >98 %. CAS No. 1010412-80-2. Molecular formula: C32H37NO6. Mole weight: 531.64. | |
| GSK3787 | ?98% (HPLC), white to off-white, powder. Group: Fluorescence/luminescence spectroscopy. | |
| GSK3787 | GSK3787 is a selective and irreversible peroxisome proliferator-activated receptor ? (PPAR?) antagonist with pIC50 of 6.6. Uses: Scientific research. Group: Signaling pathways. CAS No. 188591-46-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg. Product ID: HY-15577. | |
| GSK 3787 | GSK 3787. Group: Biochemicals. Grades: Purified. CAS No. 188591-46-0. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| GSK-3787 | GSK-3787 is a potent and selective ligand for PPARdelta with good pharmacokinetic properties. Synonyms: GSK-3787; GSK3787; GSK 3787. CAS No. 188591-46-0. Molecular formula: C15H12ClF3N2O3S. Mole weight: 392.78059. | |
| GSK3987 | GSK3987 is a pan LXRα/β agonist. Synonyms: GSK-3987; GSK 3987; 1-Benzyl-3-[(4-methoxyphenyl)amino]-4-phenyl-1H-pyrrole-2,5-dione. Grade: >98%. CAS No. 264206-85-1. Molecular formula: C24H20N2O3. Mole weight: 384.43. | |
| GSK3?, active, His tagged human | recombinant, expressed in baculovirus infected Sf9 cells, ?70% (SDS-PAGE), buffered aqueous glycerol solution. Group: Fluorescence/luminescence spectroscopy. | |
| GSK3? active human | recombinant, expressed in baculovirus infected Sf9 cells, ?80% (SDS-PAGE). Group: Fluorescence/luminescence spectroscopy. | |
| GSK-3β inhibitor 1 | GSK-3β inhibitor 1 is a glycogen synthase kinase 3β (GSK-3β) inhibitor (IC50 = 4.9 nM) with high antidiabetic efficacy. Synonyms: 3-[(Z)-(2-Pyridinyl)methylene]indoline-2-one; (3Z)-3-(2-pyridinylmethylene)-1,3-dihydro-2H-indol-2-one; (3Z)-3-(pyridin-2-ylmethylene)-1,3-dihydro-2H-indol-2-one; 2H-Indol-2-one, 1,3-dihydro-3-(2-pyridinylmethylene)-, (3Z)-. Grade: ≥95%. CAS No. 187325-53-7. Molecular formula: C14H10N2O. Mole weight: 222.24. | |
| GSK-3β inhibitor 11 | GSK-3β inhibitor 11 (compound 21) is a glycogen synthase kinase-3β ( GSK-3β ) inhibitor ( IC 50 =10.02 μM). GSK-3β inhibitor 11 can be used in neurodegenerative disease research [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 536731-65-4. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-148132. | |
| GSK-3β inhibitor 12 | GSK-3β inhibitor 12 is an inhibitor of GSK-3β, an enzyme playing an essential function in T cell differentiation and proliferation. Synonyms: GSK-3beta inhibitor 12; 2-(1H-Indol-3-yl)-N-(5-methylthiazol-2-yl)acetamide. CAS No. 784170-07-6. Molecular formula: C14H13N3OS. Mole weight: 271.34. | |
| GSK-3β inhibitor 2 | GSK-3β inhibitor 2 is a potent, selective and orally active GSK-3β inhibitor (IC50 = 1.1 nM) that can cross the blood-brain barrier and has the potential to treat Alzheimer's disease. Synonyms: 2-(2-(Cyclopropanecarboxamido)pyridin-4-yl)-4-methoxythiazole-5-carboxamide; 2-{2-[(Cyclopropylcarbonyl)amino]-4-pyridinyl}-4-methoxy-1,3-thiazole-5-carboxamide; 5-Thiazolecarboxamide, 2-[2-[(cyclopropylcarbonyl)amino]-4-pyridinyl]-4-methoxy-. Grade: ≥98%. CAS No. 1702428-31-6. Molecular formula: C14H14N4O3S. Mole weight: 318.35. | |
| GSK-3β inhibitor 3 | GSK-3β inhibitor 3, a potent, selective, irreversible and covalent glycogen synthase kinase 3β (GSK-3β) inhibitor (IC50 = 6.6 μM), is used in the study of acute promyelocytic leukemia. Synonyms: 5-Acryloyl-2-(4-fluorophenyl)-2,3-dihydrobenzo[b][1,4]thiazepin-4(5H)-one; 5-Acryloyl-2-(4-fluorophenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one; 1,5-Benzothiazepin-4(5H)-one, 2-(4-fluorophenyl)-2,3-dihydro-5-(1-oxo-2-propen-1-yl)-; 5-Acryloyl-2,3-dihydro-2-(4-fluorophenyl)-1,5-benzothiazepin-4(5H)-one. Grade: ≥95%. CAS No. 1448990-73-5. Molecular formula: C18H14FNO2S. Mole weight: 327.37. | |
| GSK-3β inhibitor 3 | GSK-3β inhibitor 3 is a potent, selective, irreversible and covalent inhibitor of Glycogen Synthase Kinase 3β (GSK-3β) , with an IC 50 of 6.6 μM. GSK-3β inhibitor 3 can be used for the research of acute promyelocytic leukemia [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1448990-73-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-141480. | |
| GSK3β inhibitor II | GSK3β inhibitor II is an inhibitor of GSK3&beta. GSK3β inhibitor II can be used for research of Alzheimers disease (AD) [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 478482-75-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-14679. | |
| GSK3β Inhibitor II | GSK3β Inhibitor II is a potent and selective inhibitor of glycogen synthase kinase-3β (GSK3β) with an IC50 value of 390 nM. Synonyms: ?Glycogen Synthase Kinase 3β?? Inhibitor II; Tip-oxadiazole; 4-[5-[[(3-iodophenyl)methyl]thio]-1,3,4-oxadiazol-2-yl]-pyridine; 2-Thio(3-iodobenzyl)-5-(1-pyridyl)-[1,3,4]-oxadiazole. Grade: ≥95%. CAS No. 478482-75-6. Molecular formula: C14H10IN3OS. Mole weight: 395.2. | |
| GSK3β Inhibitor XI | GSK3β inhibitor XI is a cell-permeable, potent and ATP-competitive inhibitor of glycogen synthase kinase 3β (GSK3β; Ki = 25 nM) which is selective for GSK3β over a panel of 79 commonly studied protein kinases. Synonyms: 3-[1-(3-hydroxypropyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-4-(2-pyrazinyl)-1H-pyrrole-2,5-dione. Grade: ≥98%. CAS No. 626604-39-5. Molecular formula: C18H15N5O3. Mole weight: 349.3. | |
| GSK3β Inhibitor XVIII | GSK3β inhibitor XVIII is a cell-permeable, potent and selective inhibitor of glycogen synthase kinase 3β (GSK3β; IC50 = 64 nM). Synonyms: [2-chloro-4-[[4-(2-thienyl)-2-pyrimidinyl]amino]phenyl](4-methyl-1-piperazinyl)-methanone. Grade: ≥98%. CAS No. 1139875-74-3. Molecular formula: C20H20ClN5OS. Mole weight: 413.9. | |
| GSK-3beta Inhibitor XXIV (2-Methyl-5- (3-[4- (methylsulfinyl) phenyl) -1-benzofuran-5-yl) -1, 3, 4-oxadiazole, Racemic) | An orally bioavailable and blood-brain-barrier permeable oxadiazolo-benzofuranyl phenyl sulfoxide compound that acts as a potent, reversible and ATP-competitive inhibitor of GSK-3b (IC50=35nM, 34 and 140nM for racemic, (S)-9b eutomer and (R)-9b distomer). The (S)-9b eutomer displays excellent selectivity (IC50 > 10uM) over Cdk1/2/5, Chk1, p38a, JNK1, MEKK1, IKKb, PKCth, CK1d, EGFR, ErbB2, Src, Lck, IR, Tie2, c-Kit, c-Met, VEGFR2, FGFR3 and PDGFRa/b, and lowers tau phosphorylation at GSK-3b-Thr205 in a CWS (cold water stress) mouse model (3mg/kg, p.o.). Group: Biochemicals. Grades: Highly Purified. CAS No. 1005201-24-0. Pack Sizes: 5mg. US Biological Life Sciences. | Worldwide |
| GSK-3beta Inhibitor XXV (GSK-3beta, N-(3-Chloro-4-methylphenyl)-5-(4-nitrophenyl)-1,3,4-oxadiazol-2-amine, 5-(4-Nitrophenyl)-N-(3-chloro-4-methyl)phenyl-1,3,4-oxadiazol-2-amine) | A blood brain barrier permeable oxadiazole compound that acts as a potent, reversible and ATP-competitive inhibitor of GSK-3b activity (IC50=17.1nM) with excellent selectivity over Cdk2 (22% inhibition at 10uM). Shown to elevate liver glycogen levels by ~3.5- and ~4.3-fold in C57BL/6N mice when dosed at 5 and 15mg/kg (i.p.) amounts. Group: Biochemicals. Grades: Highly Purified. Pack Sizes: 10mg. Molecular Formula: C??H??ClN?O?. US Biological Life Sciences. | Worldwide |
| GSK-3 beta Inhibitor XXVII (3-Amino-6-(4-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide, HCl) | A cell-permeable pyridinyl pyrazinecarboxamide compound that acts as a highly potent, reversible, and ATP-competitive inhibitor of GSK-3b (Ki=4.9nM) with ~110-fold greater selectivity over Cdk2 (Ki=540nM). Shows only a trivial effect on the activities of 26-related kinases at much higher doses. Blocks GSK-3b-mediated phosphorylation of Ser396 in stably transfected 3T3 fibroblasts expressing four-repeat tau protein (IC50=76nM). Readily crosses blood-brain barrier and exhibits desirable bioavailability and aqueous solubility. Group: Biochemicals. Grades: Highly Purified. Pack Sizes: 10mg. US Biological Life Sciences. | Worldwide |
| GSK-3beta Inhibitor XXVII, CESI (2-(3-chloro-4-hydroxyphenyl)-8-(1,1-dioxidoisothiazolidin-2-yl)-3-hydroxy-6-methyl-4H-chromen-4-one) | A cell-permeable, 3-hydroxychromone derived compound that acts as a selective and reversible inhibitor of GSK-3beta (IC50 < 100nM). Shown to increase phosphorylation at Ser9. Does not show any inhibitory effect on a panel of 15 other protein kinases, including AMPK and Akt. By blocking GSK-3beta activity, it acts as a positive regulator of b-catenin signaling. Does not affect the viability or the growth rate of 3T3-L1 preadipocytes, however, it significantly reduces their differentiation into adipocytes ( 50 to 100nM). Exerts anti-adipogenic activity by down-regulating C/EBPa and PPARg. Shown to reduce adipocyte size and diminish weight gain in diet-induced obese mice without affecting their daily food intake. Group: Biochemicals. Grades: Highly Purified. Pack Sizes: 10mg. Molecular Formula: C??H??ClNO?S, Primary Target: GSK3b. US Biological Life Sciences. | Worldwide |
| GSK-3/CDK5/CDK2-IN-1 | GSK-3/CDK5/CDK2-IN-1, an inhibitor of CDK5, CDK2 and GSK-3, can be used in the study of cancer and neurodegenerative diseases. (Extracted from patent WO2002010141A1, example 9a). Synonyms: 2-Naphthaleneacetamide, N-[1-[cis-3-(acetylamino)cyclobutyl]-1H-imidazol-4-yl]-; N-(1-((1s,3s)-3-acetamidocyclobutyl)-1H-imidazol-4-yl)-2-(naphthalen-2-yl)acetamide; N-[1-(cis-3-Acetamidocyclobutyl)-1H-imidazol-4-yl]-2-(2-naphthyl)acetamide. Grade: ≥98%. CAS No. 395074-72-3. Molecular formula: C21H22N4O2. Mole weight: 362.42. | |
| GSK-3?, His Tag, Human, Recombinant, E. coli | GSK-3?, Human, Recombinant, E. coli, is a dual specificity kinase that plays important roles in insulin- and Wnt-mediated signaling. It is inactivated by phosphorylation at Ser9. Group: Fluorescence/luminescence spectroscopy. | |
| GSK-3 inhibitor 1 | GSK-3 inhibitor 1 is a potent GSK-3 inhibitor. Grade: >98%. CAS No. 603272-51-1. Molecular formula: C22H17ClFN5O2. Mole weight: 437.85. | |
| GSK-3 inhibitor 3 | GSK-3 inhibitor 3 is a selective, orally active and brain-penetrant inhibitor of GSK-3 , with IC 50 s of 0.35 nM and 0.25 nM for GSK-3α and GSK-3β, respectively. GSK-3 inhibitor 3 lowers levels of tau protein phosphorylation at S396 in a triple-transgenic mouse Alzheimers disease model, with IC 50 of 10 nM. GSK-3 inhibitor 3 can be used for neurological disease research [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2227279-84-5. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-154851. | |
| GSK-3 Inhibitor, AR-A014418, (N-[(4-Methoxyphenyl)methyl]-N-(5-nitro-2-thiazolyl)urea) | Cell-permeable. A selective glycogen synthase kinase 3 (GSK-3) inhibitor (IC50 = 104nm). Inhibition is competitive with respect to ATP (Ki = 38nm). Exhibits specificity for GSK-3 over cdk2 and cdk5 (IC50 values are > 100 =um) and over 26 other kinases. Inhibits b-amyloid-mediated neurodegeneration in hippocampal slices. Group: Biochemicals. Grades: Highly Purified. Pack Sizes: 2mg. Molecular Formula: C??H??N?O?S. US Biological Life Sciences. | Worldwide |
| GSK-3? Inhibitor I - CAS 327036-89-5 | The GSK-3? Inhibitor I, also referenced under CAS 327036-89-5, controls the biological activity of GSK-3?. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications. Group: Fluorescence/luminescence spectroscopy. | |
| GSK-3? Inhibitor II - CAS 478482-75-6 | The GSK-3? Inhibitor II, also referenced under CAS 478482-75-6, controls the biological activity of GSK-3?. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications. Group: Fluorescence/luminescence spectroscopy. | |
| GSK 3 Inhibitor IX | GSK 3 Inhibitor IX (6-Bromoindirubin-3'-oxime; BIO) is a potent, selective, reversible and ATP-competitive inhibitor of GSK-3?/? and CDK1-cyclinB complex with IC50s of 5 nM/320 nM/80 nM for (GSK-3?/?)/CDK1/CDK5, respectively. Uses: Scientific research. Group: Signaling pathways. Alternative Names: 6-Bromoindirubin-3'-oxime; BIO; MLS 2052. CAS No. 667463-62-9. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 50 mg. Product ID: HY-10580. | |
Our database is helping our users find suppliers everyday.
